Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Healsea® Hypertonic Nasal Spray 2.7% in the Treatment of Acute Infectious Rhinitis in Adults

NCT05819190 is registered in ClinicalTrials.gov with Lallemand Pharma AG as lead sponsor.

NCT NCT05819190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05819190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Healsea® Hypertonic Nasal Spray 2.7% in the Treatment of Acute Infectious Rhinitis in Adults
Lead sponsor
Lallemand Pharma AG
Phase
Not applicable
Overall status
Completed
Start date
December 14, 2022
Completion date
January 31, 2023
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

common cold